The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
Open accessAbstract
Ovarian cancer (OC) is the fifth most common cause of cancer death in women. Although significant progress has been made in the treatment of OC, the majority of patients experience disease recurrence and receive second-line and sometimes several lines of treatment. Here we review the options available for the treatment of recurrent disease and discuss how different agents are selected, combined and offered in a rationale sequence in the context of multidisciplinary care. We reviewed published work between 1990 and 2013 and meeting abstracts related to the use of chemotherapy and surgery in patients with recurrent ovarian cancer. We discuss treatment regimens, efficacy endpoints and safety profiles of the different therapies. Platinum-based drugs are the most active agents and are selected on the basis of a probability of response to retreatment. Nonplatinum-based chemotherapy regimens are usually given in the ‘platinum-resistant’ setting and have a modest effect on outcome. Molecular targeted therapy of ovarian cancer given alone or integrated with chemotherapy is showing promising results. Many patients are now receiving more than one line of therapy for recurrent disease, usually platinum based until platinum resistance emerges. The sequential use of chemotherapy regimens and the incorporation of molecularly targeted treatments, either alone or in combination with chemotherapy, have over the last decade significantly extended the median survival of patients with ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Self-citationPujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
Self-citationThe anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397
Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., & Sessa, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt333 · Cited by 1,104
Self-citationBurger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, W., Almadrones, L., & Lewis, J. L. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.389 · Cited by 839
Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G., Kimmig, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0913 · Cited by 754
Platinum Resistance: The Role of DNA Repair Pathways
Martin, L. P., Hamilton, T. C., & Schilder, R. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2238 · Cited by 751
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
ten Bokkel Huinink, W., Gore, M., Carmichael, J., Gordon, A., Malfetano, J., Hudson, I., Broom, C., Scarabelli, C., Davidson, N., Spanczynski, M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2183 · Cited by 663
Rustin, G. J. S., Vergote, I., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., du Bois, A., Kristensen, G., Jakobsen, A., Sagae, S., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e3182070f17 · Cited by 625
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Rustin, G. J., van der Burg, M. E., Griffin, C. L., Guthrie, D., Lamont, A., Jayson, G. C., Kristensen, G., Mediola, C., Coens, C., Qian, W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61268-8 · Cited by 599
Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7519 · Cited by 575
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
Verhaak, R. G. W., Tamayo, P., Yang, J.-Y., Hubbard, D., Zhang, H., Creighton, C. J., Fereday, S., Lawrence, M., Carter, S. L., Mermel, C. H., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65833 · Cited by 569
Garcia, A. A., Hirte, H., Fleming, G., Yang, D., Tsao-Wei, D. D., Roman, L., Groshen, S., Swenson, S., Markland, F., Gandara, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1939 · Cited by 547
Katsumata, N., Yasuda, M., Isonishi, S., Takahashi, F., Michimae, H., Kimura, E., Aoki, D., Jobo, T., Kodama, S., Terauchi, F., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70363-2 · Cited by 480
Mutch, D. G., Orlando, M., Goss, T., Teneriello, M. G., Gordon, A. N., McMeekin, S. D., Wang, Y., Scribner, D. R., Marciniack, M., Naumann, R. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6735 · Cited by 426
2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer
Stuart, G. C. E., Kitchener, H., Bacon, M., duBois, A., Friedlander, M., Ledermann, J., Marth, C., Thigpen, T., & Trimble, E. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31821b2568 · Cited by 425
Self-citationTrabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4037 · Cited by 395
Gore, M. E., Fryatt, I., Wiltshaw, E., & Dawson, T. (1990) · Gynecologic Oncology · doi:10.1016/0090-8258(90)90174-j · Cited by 381
Hanker, L. C., Loibl, S., Burchardi, N., Pfisterer, J., Meier, W., Pujade-Lauraine, E., Ray-Coquard, I., Sehouli, J., Harter, P., & du Bois, A. (2012) · Annals of Oncology · doi:10.1093/annonc/mds203 · Cited by 329
Eisenhauer, E. A., Vermorken, J. B., & van Glabbeke, M. (1997) · Annals of Oncology · doi:10.1023/a:1008240421028 · Cited by 265
Naumann, R. W., Coleman, R. L., Burger, R. A., Sausville, E. A., Kutarska, E., Ghamande, S. A., Gabrail, N. Y., DePasquale, S. E., Nowara, E., Gilbert, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.7685 · Cited by 238
Clinical Trials in Recurrent Ovarian Cancer
Friedlander, M., Trimble, E., Tinker, A., Alberts, D., Avall-Lundqvist, E., Brady, M., Harter, P., Pignata, S., Pujade-Lauraine, E., Sehouli, J., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31821bb8aa · Cited by 224
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
Yap, T. A., Sandhu, S. K., Carden, C. P., & de Bono, J. S. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20095 · Cited by 208
Ovarian Cancer, Version 3.2012
Morgan, R. J., Alvarez, R. D., Armstrong, D. K., Burger, R. A., Castells, M., Chen, L.-M., Copeland, L., Crispens, M. A., Gershenson, D., Gray, H., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0140 · Cited by 195
Wagner, U., Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I., Piccirillo, M. C., Fossati, R., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.307 · Cited by 189
Piccart, M. J., Green, J. A., Lacave, A. J., Reed, N., Vergote, I., Benedetti-Panici, P., Bonetti, A., Kristeller-Tome, V., Fernandez, C. M., Curran, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1193 · Cited by 159
Gotlieb, W. H., Amant, F. C., Advani, S. H., Goswami, C., Hirte, H. W., Provencher, D. M., Somani, N., Yamada, S., Tamby, J., & Vergote, I. B. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70338-2 · Cited by 151
Overview of anti-angiogenic agents in development for ovarian cancer
Burger, R. A. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.11.035 · Cited by 150
Ovarian Cancer, Version 2.2013
Morgan, R. J., Alvarez, R. D., Armstrong, D. K., Burger, R. A., Chen, L.-M., Copeland, L. J., Crispens, M. A., Gershenson, D. M., Gray, H. J., Hakam, A., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0142 · Cited by 142
Rosenberg, P., Andersson, H., Boman, K., Ridderheim, M., Sorbe, B., Puistola, U., & Parö, G. (2002) · Acta Oncologica · doi:10.1080/028418602320404998 · Cited by 137
Zang, R., Harter, P., S., D., Sehouli, J., Jiang, R., Trope, C. G., Ayhan, A., Cormio, G., Xing, Y., Wollschlaeger, K., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.328 · Cited by 135
Colombo, N., Kutarska, E., Dimopoulos, M. A., Bae, D., Rzepka-Górska, I., Bidziński, M., Scambia, G., Engelholm, S. A., Joly, F., Weber, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8082 · Cited by 126
Alberts, D. S., Liu, P. Y., Wilczynski, S. P., Clouser, M. C., López, A. M., Michelin, D. P., Lanzotti, V. J., & Markman, M. M. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.08.075 · Cited by 115
Rose, P. G., Mossbruger, K., Fusco, N. L., Smrekar, M., Eaton, S., & Rodriguez, M. J. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6850 · Cited by 102
Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
van der Burg, M. E. L., de Wit, R., van Putten, W. L. J., Logmans, A., Kruit, W. H. J., Stoter, G., & Verweij, J. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600002 · Cited by 87
Bolis, G., Scarfone, G., Giardina, G., Villa, A., Mangili, G., Melpignano, M., Presti, M., Tateo, S., Franchi, M. P., & Parazzini, F. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6151 · Cited by 86
Raja, F. A., Counsell, N., Colombo, N., Pfisterer, J., du Bois, A., Parmar, M., Vergote, I. B., González-Martı́n, A., Alberts, D. S., Plante, M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt406 · Cited by 82
Self-citationBuda, A. A., Floriani, I., Rossi, R., Colombo, N., Torri, V., Conte, P., Fossati, R., Ravaioli, A., & Mangioni, C. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601787 · Cited by 80
Pinato, D. J., Graham, J., Gabra, H., & Sharma, R. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.04.004 · Cited by 76
Sharma, R., Graham, J., Mitchell, H., Brooks, A., Blagden, S. P., & Gabra, H. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604914 · Cited by 65
Kaye, S. B., Colombo, N., Monk, B. J., Tjulandin, S., Kong, B., Roy, M., Chan, S. Y. T., Filipczyk−Cisarż, E., Hagberg, H., Vergote, I. B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq353 · Cited by 60
Meier, W., du Bois, A., Reuß, A., Kuhn, W. C., Olbricht, S., Gropp, M., Richter, B., Lück, H., Kimmig, R., & Pfisterer, J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.04.026 · Cited by 54
Vergote, I. B., Calvert, H., Kania, M. K., Kaiser, C. J., Zimmermann, A. H., & Sehouli, J. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.12.013 · Cited by 51
Bafaloukos, D. I., Linardou, H., Aravantinos, G., PAPADIMITRIOU, C. A., Bamias, A., Fountzilas, G., Kalofonos, H. P., Kosmidis, P., Timotheadou, E. T., Makatsoris, T., et al. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-3 · Cited by 49
Horowitz, N. S., Hua, J., Gibb, R. K., Mutch, D. G., & Herzog, T. J. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.03.047 · Cited by 44
Rustin, G. J. S., Reed, N. S., Jayson, G. C., Ledermann, J. A., Adams, M., Perren, T. J., Poole, C. J., Lind, M., Persic, M., Essapen, S., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq780 · Cited by 28
Self-citationHan, Y. K., Huang, H., Xiao, Z., Zhang, W., Cao, Y., Qu, L., & Shou, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052745 · Cited by 24
Cited by
Treatment of epithelial ovarian cancer
Kuroki, L., & Guntupalli, S. R. (2020) · BMJ · doi:10.1136/bmj.m3773 · Cited by 873
Moore, K. N., Oza, A. M., Colombo, N., Oaknin, A., Scambia, G., Lorusso, D., Konecny, G. E., Banerjee, S., Murphy, C. G., Tanyi, J. L., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.017 · Cited by 305
Albumin-bound paclitaxel in solid tumors: clinical development and future directions
Kundranda, M., & Niu, J. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s88023 · Cited by 255
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments
Marchetti, C., De Felice, F., Romito, A., Iacobelli, V., Sassu, C. M., Corrado, G., Ricci, C., Scambia, G., & Fagotti, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.08.011 · Cited by 139
Moore, K. N., O'Malley, D. M., Vergote, I., Martin, L. P., Gonzalez-Martin, A., Malek, K., & Birrer, M. J. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.07.017 · Cited by 82
Metadata
- Authors
- Luvero, D., Milani, A., & Ledermann, J. A.
- Venue
- Therapeutic Advances in Medical Oncology
- Publisher
- SAGE Publications
- Published
- 2014-08-05
- Volume
- 6
- Issue
- 5
- Pages
- 229-239
- ISSN
- 1758-8340 (ISSN-L)
- 1758-8359
- OpenAlex
- W2122624385
- Cited by
- 260
- References
- 57
- FWCI
- 18.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.